A Research Study of JNJ-26854165 to Determine the Safety and Dose in Patients With Advanced Stage or Refractory Solid Tumors.

NCT00676910 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

71

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: JNJ-26854165

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.